US20150064158A1 - Sense-improving agent - Google Patents

Sense-improving agent Download PDF

Info

Publication number
US20150064158A1
US20150064158A1 US13/981,698 US201213981698A US2015064158A1 US 20150064158 A1 US20150064158 A1 US 20150064158A1 US 201213981698 A US201213981698 A US 201213981698A US 2015064158 A1 US2015064158 A1 US 2015064158A1
Authority
US
United States
Prior art keywords
milk
basic protein
protein fraction
derived basic
sensation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/981,698
Other languages
English (en)
Inventor
Ken Katoh
Noriko Ueda
Hiroshi Ueno
Yuko Ono
Norimichi Nakahata
Takahiro Moriya
Daisaku Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Megmilk Snow Brand Co Ltd
Original Assignee
Megmilk Snow Brand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megmilk Snow Brand Co Ltd filed Critical Megmilk Snow Brand Co Ltd
Assigned to MEGMILK SNOW BRAND CO., LTD. reassignment MEGMILK SNOW BRAND CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NAKAHATA, HIROKO, KOBAYASHI, DAISAKU, MORIYA, TAKAHIRO, KATOH, KEN, ONO, YUKO, UEDA, NORIKO, UENO, HIROSHI
Publication of US20150064158A1 publication Critical patent/US20150064158A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A23K1/1631
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • A23K20/147Polymeric derivatives, e.g. peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23L1/3056
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • A23L2/66Proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018Hydrolysed proteins; Derivatives thereof from animals from milk
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0065Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21001Chymotrypsin (3.4.21.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21004Trypsin (3.4.21.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23Aspartic endopeptidases (3.4.23)
    • C12Y304/23002Pepsin B (3.4.23.2)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10General cosmetic use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y111/00Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01Peroxidases (1.11.1)
    • C12Y111/01007Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87Re-use of by-products of food processing for fodder production

Definitions

  • the invention relates to a skin sensitivity improving agent that includes a basic protein fraction or a degraded basic protein fraction as an active ingredient and improves deterioration in peripheral sensation, and a skin sensitivity improving food, drink, feed, or cosmetic that includes the skin sensitivity improving agent.
  • Deterioration in peripheral sensation can be known as one of the age-related symptoms.
  • the deterioration in peripheral sensation also occurs due to not only aging, but also diseases such as diabetes and the like.
  • Deterioration in peripheral sensation may occur following troubles; for example, as it can't feel hot immediately when touching a hot object, a risk of burns or the like increases or the discovery of an injury becomes delay due to deterioration in pain sensation.
  • studies that improve deterioration in peripheral sensation due to ageing or diseases have been conducted.
  • sphingomyelinase or phosphatidylcholine-specific phospholipase C which are enzymes that increase biosynthesis of endogenous ceramides promote differentiation of PC-12 cells which is one of the neural cell lines through the secretion of neurotrophic factors from Swiss 3T3 fibroblast cells.
  • ceramides and the above enzymes are not food ingredients, it is necessary to take account of safety. Therefore, a safe agent that is effective to improve deterioration in peripheral sensation through daily intake or skin application has been desired.
  • Patent Document 1 JP-A-H08-151331
  • Patent Document 2 JP-A-2003-146883
  • Non-patent Document 1 Norimichi Nakahata and Satoko Okubo, Studies on Expression Mechanism of Physiological Functions of Ceramides Having Skin Protection Function, Annual Report of Cosmetology, Vol. 10, 2002
  • An object of the present invention is to provide a safe and skin sensitivity improving agent that is effective to improve deterioration in peripheral sensation through daily intake or skin application.
  • Another object of the present invention is to provide a sensation-improving food, drink, feed, or cosmetic that is effective to improve deterioration in peripheral sensation through oral intake or skin application.
  • milk-derived basic protein fraction a basic protein fraction derived from milk
  • degraded milk-derived basic protein fraction a degraded basic protein fraction obtained by degrading the milk-derived basic protein fraction using a protease
  • the inventors thus completed a skin sensitivity improving agent by utilizing the milk-derived basic protein fraction and/or the degraded milk-derived basic protein fraction as an active ingredient.
  • a skin sensitivity improving food, drink, feed, or cosmetic can be obtained by adding the skin sensitivity improving agent to a food, drink, feed, or the like, respectively.
  • the invention provides the following.
  • a skin sensitivity improving agent including a milk-derived basic protein fraction as an active ingredient.
  • a skin sensitivity improving agent including a degraded milk-derived basic protein fraction as an active ingredient, the degraded milk-derived basic protein fraction being obtained by treating the milk-derived basic protein fraction according to any one of (1) to (3) with a protease.
  • protease is at least one protease selected from the group consisting of pepsin, trypsin, chymotrypsin, and pancreatin.
  • a skin sensitivity improving food, drink, feed, or cosmetic including the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction according to any one of (1) to (5).
  • a method for improving sensation of a mammal including administering a composition that includes a milk-derived basic protein fraction to the mammal via oral administration or application on skin.
  • a method for improving sensation of a mammal including administering a composition that includes a degraded milk-derived basic protein fraction to the mammal via oral administration or application on skin, the degraded milk-derived basic protein fraction being obtained by treating the milk-derived basic protein fraction according to any one of (7) to (9) with a protease.
  • protease is at least one protease selected from the group consisting of pepsin, trypsin, chymotrypsin, and pancreatin.
  • the invention can thus provide a skin sensitivity improving agent that includes a milk-derived basic protein fraction or a degraded milk-derived basic protein fraction as an active ingredient, and a skin sensitivity improving food, drink, feed, or cosmetic that includes a milk-derived basic protein fraction or a degraded milk-derived basic protein fraction.
  • the skin sensitivity improving agent according to the invention exhibits an effect that improves deterioration in peripheral sensation.
  • the invention is characterized in that a milk-derived basic protein fraction or a degraded milk-derived basic protein fraction are used as active ingredients.
  • the milk-derived basic protein fraction is obtained from mammalian milk such as cow milk, human milk, goat milk, or ewe milk, and the degraded milk-derived basic protein fraction is obtained by treating the milk-derived basic protein fraction with a protease.
  • the milk-derived basic protein fraction has the following properties.
  • the milk-derived basic protein fraction comprises several types of proteins having a molecular weight of 3,000 to 80,000 determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
  • the milk-derived basic protein fraction includes proteins in an amount of 95 wt % or more, and includes a small amount of fats and ash.
  • the milk-derived basic protein fraction mainly includes lactoferrin and lactoperoxidase as proteins.
  • the milk-derived basic protein fraction has basic amino acids, such as lysine, histidine, arginine and the like in an amount of 15 wt % or more based on the total amino acids.
  • the basic protein fraction may be obtained by applying a milk-derived raw material, such as skim milk, whey or the like to a cation-exchange resin to adhered the basic proteins on the cation-exchange resin, eluting the basic protein fraction adhered on the cation-exchange resin by using an eluant having a sodium chloride concentration of 0.1 to 1 M, collecting the eluted fraction, which is desalted and concentrated by using a reverse osmosis (RO) membrane, electrodialysis (ED), or the like, and optionally drying the resulting product, for example.
  • a milk-derived raw material such as skim milk, whey or the like
  • a cation-exchange resin to adhered the basic proteins on the cation-exchange resin
  • eluant having a sodium chloride concentration of 0.1 to 1 M collecting the eluted fraction, which is desalted and concentrated by using a reverse osmosis (RO) membrane, electrodialysis (ED
  • the following methods have been known as a method of obtaining a milk-derived basic protein fraction; a method of obtaining the fraction by contacting milk or a milk-derived raw material with a cation exchanger to adhere on the cation exchanger, and eluting the basic protein fraction adhered on the cation exchanger using an eluant having a pH of more than 5 and an ionic strength of more than 0.5 (JP-A-5-202098), a method of obtaining the fraction using an alginic acid gel (JP-A-61-246198), a method of obtaining the fraction from whey using porous inorganic particles (JP-A-1-86839), a method of obtaining the fraction from milk using a sulfated ester compound (JP-A-63-255300), or the like.
  • a basic protein fraction obtained by such a method may be used in the invention.
  • the degraded milk-derived basic protein fraction has the same amino acid composition as that of the milk-derived basic protein fraction.
  • the degraded milk-derived basic protein fraction may be obtained as a peptide composition having an average molecular weight of 4,000 or less by treating a milk-derived basic protein fraction obtained by the above methods with a protease such as pepsin, trypsin, or chymotrypsin, and optionally treating the resulting product with a protease such as pancreatin or the like.
  • the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction may be used directly as the skin sensitivity improving agent according to the invention.
  • the skin sensitivity improving agent may be further mixed a raw material or the like that is normally used for drugs, food, drink, and feed, such as saccharides, lipids, proteins, vitamins, minerals, or flavors, or the like, in addition to the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction, and the skin sensitivity improving agent may be prepared into a powdered drug, granules, a tablet, a capsule, a drinkable preparation, or the like by a conventional method.
  • the skin sensitivity improving agent may also be used in common application form such as emulsion, cream, lotion, massage mask, or the like.
  • the skin sensitivity improving agent in preparation form may be prepared by a conventional method while appropriately adding the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction used as an active ingredient in the invention, and may be used as a cosmetic.
  • Another component e.g., ceramide, sphingomyelinase, or sphingomyelin or the like that exhibits a skin sensitivity improving effect may be used in combination with the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction.
  • the peripheral sensation was improved by orally administering the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 10 mg/kg weight or more, and preferably 20 mg/kg weight or more per mouse.
  • the skin liniment may contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 0.001 to 40 wt %, and preferably 0.1 to 10 wt %, based on the total amount of the skin liniment.
  • a skin sensitivity improving food or drink according to the invention may be produced by mixing the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction to a normal food or drink, such as yogurt, milk-based drink, wafer, dessert or the like. It is preferable that the skin sensitivity improving food or drink contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 0.5 to 2000 mg per 100 g of the food or drink so that an adult can take the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 10 mg/day or more, although the content of the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is appropriately determined depending on the type of the food or drink.
  • a skin sensitivity improving feed according to the invention may be produced by adding the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction to a normal feed, such as livestock feed, pet food or the like. It is preferable that the skin sensitivity improving feed contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 0.5 to 2000 mg per 100 g of the feed so that the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is taken in an amount of 10 mg/day or more.
  • the method of mixing the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction may not be particularly limited.
  • the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is suspended or dissolved in deionized water, and the mixture is stirred and prepared in the form of a drug, food, drink, or feed.
  • the stirring/mixing conditions are not particularly limited as long as the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is uniformly mixed.
  • the mixture may be stirred/mixed using an ultra-disperser, a TK-homomixer, or the like.
  • the solution containing the composition may optionally be concentrated using an RO membrane, or freeze-dried so that the solution can be easily used for a drug, food, drink, or feed.
  • a sterilization treatment conventionally used in the production of a drug, food, drink, or feed may be employed in the invention. Dry-heat sterilization may also be employed for a powdery product. Therefore, it is possible to produce drugs, food, drink, and feed in various forms (e.g., liquid, gel, powder, or granules) that contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction of the invention.
  • a column (diameter: 5 cm, height: 30 cm) filled with 400 g of sulfonated Chitopearl (cation-exchange resin; manufactured by Fuji Spinning Co., Ltd.) was sufficiently washed with deionized water.
  • 40 1 (liters) of unsterilized skim milk (pH 6.7) was passed through the column at a flow rate of 25 ml/min.
  • the column was then sufficiently washed with deionized water, and a basic protein fraction adhered on the resin was eluted with a 0.02 M carbonate buffer solution (pH 7.0) containing 0.98 M sodium chloride.
  • the eluate was desalted and concentrated using a reverse osmosis (RO) membrane, and freeze-dried to obtain 21 g of powdery milk-derived basic protein fraction (Example product 1).
  • the molecular weight of the milk-derived basic protein fraction determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was distributed in the range of 3000 to 80,000.
  • the milk-derived basic protein fraction had the composition shown in Table 1.
  • the milk-derived basic protein fraction was hydrolyzed using 6 N hydrochloric acid at 110° C. for 24 hours, and the amino acid composition of the milk-derived basic protein fraction was analyzed using an amino acid analyzer (“L-8500” manufactured by Hitachi Ltd.). The results are shown in Table 2.
  • the protein composition of the milk-derived basic protein fraction was analyzed by ELI SA. As shown in Table 3, the milk-derived basic protein fraction had a lactoferrin content and a lactoperoxidase content of 40% or more.
  • the basic protein fraction may be used directly as the skin sensitivity improving agent according to the invention.
  • a column (diameter: 100 cm, height: 10 cm) filled with 30 kg of cation-exchange resin (SP Toyopearl; manufactured by Tosoh Corporation) was sufficiently washed with deionized water.
  • the column was then sufficiently washed with deionized water, and a basic protein fraction adhered on the resin was eluted with a 0.1 M citrate buffer solution (pH 5.7) containing 0.9 M sodium chloride.
  • the eluate was desalted and concentrated by electrodialysis (ED), and freeze-dried to obtain 183 g of a powdery milk-derived basic protein fraction (Example product 2).
  • the milk-derived basic protein fraction thus obtained may be used directly as the skin sensitivity improving agent according to the invention.
  • Example product 3 50 g of the milk-derived basic protein fraction obtained in Example 1 was dissolved in 10 1 of distilled water. After the addition of 1% pancreatin (manufactured by Sigma), the mixture was reacted at 37° C. for 2 hours. After completion of the reaction, the protease was inactivated by heating the mixture at 80° C. for 10 minutes to obtain 48.3 g of a degraded milk-derived basic protein fraction (Example product 3). The degraded milk-derived basic protein fraction thus obtained may be used directly as the skin sensitivity improving agent according to the invention.
  • Swiss 3T3 cells which is one of the fibroblast cell lines known to be present in skin, were cultured for 2 days under the condition that Example product 1 of the milk-derived basic protein fraction or Example product 3 of the degraded milk-derived basic protein fraction was added at a concentration of 0.03 to 1%, respectively (Example product 1: group A, Example product 3: group B).
  • Swiss 3T3 cells were cultured for 2 days without adding Example product 1 of the milk-derived basic protein fraction or Example product 3 of the degraded milk-derived basic protein fraction (group C).
  • PC-12 cells which is one of the neural cell lines, were cultured adding the culture medium of Swiss 3T3 cells, and morphological differentiation of the PC-12 cells was observed.
  • PC-12 cells were highly differentiated when adding the culture mediums of the group A or B.
  • the above experiment was repeated several times, and the differentiation ratio was determined using an optical microscope. It was confirmed that 95% or more of the cells were differentiated in both cases of group A and B. In contrast, PC-12 cells were not differentiated when adding the culture medium of the group C. No differentiation was observed using an optical microscope when the experiment was repeated several times. It was thus confirmed that the milk-derived basic protein fraction obtained in Example 1 and the degraded milk-derived basic protein fraction obtained in Example 3 promoted differentiation of PC-12 cells which is one of the neural cell lines.
  • a skin sensitivity improving effect was evaluated by the hot plate test that is a thermal stimulation behavioristic approach developed by Woolfe and MacDonald.
  • 24-week-old hairless mice (Hos:HR-1) were divided into three groups (10 mice/group).
  • Example product 2 milk-derived basic protein fraction
  • Example product 2 milk-derived basic protein fraction
  • Each mouse was placed on a hot plate at 54° C., and the time elapsed until the mouse made an escape behavior such as taking off the foot from the hot plate, standing up, or jumping was measured.
  • the maximum time of escape behavior positive reaction time that is time until the mouse made an escape behavior after applying thermal stimulation was set to 30 seconds. When the escape behavior positive reaction time was 30 seconds or more, the escape behavior positive reaction time was determined to be 30 seconds. The results are shown in Table 4.
  • Example product 2 milk-derived basic protein fraction
  • Example product 2 milk-derived basic protein fraction
  • Healthy elderly persons (average age: 75 ⁇ 3) who suffered deterioration in sensation in the hands were divided into following five groups (10 subjects/group).
  • the pain sensation was evaluated using five pins having different thickness at five fulcrum positions.
  • the thinnest pin 1 was rolled along the medial side of the arm, and the subject was asked about the degree of normal pain sensation.
  • the pin 1 was then rolled along the palm and the bottom of the foot while sequentially changing the holder fulcrum position to determine the fulcrum position at which the same pain sensation degree as the first pain sensation occurred. (Evaluation method)
  • the algesiometer is designed so that the pain sensation occurs to the same extent between when rolling the pin 1 (fulcrum: 50 g) along the medial side of the arm and when rolling the pin 2 (fulcrum: 50 g) along the palm.
  • the pain sensation was evaluated as follows in accordance with the instruction manual. The pain sensation was evaluated by points, and the average points were calculated.
  • Example product 1 milk-derived basic protein fraction
  • Example product 3 degraded milk-derived basic protein fraction
  • Example product 1 milk-derived basic protein fraction
  • Example product 3 degraded milk-derived basic protein fraction
  • Deterioration in sensation is expected to be improved when an adult takes the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 10 mg/day or more generally, and preferably 20 mg/day or more.
  • a skin sensitivity improving cosmetic was prepared by mixing the degraded milk-derived basic protein fraction (Example product 3) obtained in Example 3 with the raw materials in the ratio shown in Table 9.
  • Healthy elderly persons who suffered deterioration in sensation in the hands were divided into groups A and B (15 subjects/group).
  • the subjects of the group A were applied the cosmetic (cream) that was prepared in the same manner as Example product 4, but did not contain a skin sensitivity improving agent, once daily to whole of the hands and the feet thereof, and the subjects of the group B were applied the skin sensitivity improving cosmetic (cream) obtained in Example 4 once daily to whole of the hands and the feet thereof.
  • the application period was 6 weeks.
  • the pain sensation in the palm and the arch of the foot was measured by 4 criteria (normal, deterioration I, deterioration II, or deterioration III) before the application and after the application for 6 weeks with respect to the pain sensation in the medial side of the arm using a pain/touch-pressure sensation measuring device (Algesiometer; manufactured by Intercross Ltd.) in accordance with the instruction manual. After the completion of the application for 6weeks, a questionnaire survey on an improvement in sensation in the hands was carried out to each subject. The results are shown in Tables 10 to 13. The measurement was performed in the same manner as in Test Example 3.
  • the sensation in the palm and the bottom of the foot tended to be improved by applying the skin sensitivity improving cosmetic (cream) of Example product 4 . It was thus confirmed that deterioration in sensation, particularly peripheral sensation, is expected to be improved by applying cream that includes the skin sensitivity improving agent according to the invention.
  • Example product 1 milk-derived basic protein fraction
  • Example product 1 milk-derived basic protein fraction
  • deionized water deionized water
  • the solution was stirred by a TK-homomixer (“TK ROBO MICS” manufactured by PRIMIX Corporation) at 6000 rpm for 30 minutes to obtain a basic protein fraction solution having a basic protein fraction content of 100 mg/100 g. 4.0 kg of casein, 5.0 kg of a soybean protein, 1.0 kg of fish oil, 3.0 kg of perilla oil, 18.0 kg of dextrin, 6.0 kg of a mineral mixture, 1.95 kg of a vitamin mixture, 2.0 kg of an emulsifying agent, 4.0 kg of a stabilizer, and 0.05 kg of essence were added to 5.0 kg of the milk-derived basic protein fraction solution.
  • TK ROBO MICS manufactured by PRIMIX Corporation
  • a retort pouch (200 ml) was filled with the mixture.
  • the mixture was then sterilized using a retort sterilizer (class-1 pressure vessel, “RCS-4CRTGN” manufactured by Hisaka Works, Ltd.) at 121° C. for 20 minutes to obtain 50 kg of a skin sensitivity improving liquid nutrient composition.
  • the resulting skin sensitivity improving liquid nutrient composition was not observed any precipitation and the like, and did not exhibit abnormal flavor.
  • the skin sensitivity improving liquid nutrient composition contained the milk-derived basic protein fraction in an amount of 10 mg/100 g.
  • Example product 2 milk-derived basic protein fraction
  • Example product 2 milk-derived basic protein fraction
  • the solution was stirred using an ultra-disperser (“ULTRA-TURRAX T-25” manufactured by IKA Japan) at 9500 rpm for 30 minutes.
  • 40 g sorbitol, 2 g of a sour agent, 2 g of essence, 5 g of pectin, 5 g of whey protein concentrate, 1 g of calcium lactate, and 235 g of deionized water were added to the solution. After stirring the mixture, the mixture was filled in a cheer pack (200 ml). After sterilizing the mixture at 85° C.
  • the skin sensitivity improving gel-like food contained the milk-derived basic protein fraction in an amount of 200 mg/100 g.
  • Example product 3 degraded milk-derived basic protein fraction
  • the solution was stirred using an ultra-disperser (“ULTRA-TURRAX T-25” manufactured by IKA Japan) at 9500 rpm for 30 minutes.
  • the resulting mixture was filled into a glass bottle (100 ml).
  • the bottle was sealed to obtain ten bottles of skin sensitivity improving drink (100 ml/ bottle).
  • the resulting skin sensitivity improving drink was not observed any precipitation, and did not exhibit abnormal flavor.
  • the skin sensitivity improving drink contained the degraded milk-derived basic protein fraction in an amount of 400 mg/100 g.
  • Example product 3 degraded milk-derived basic protein fraction
  • Example product 3 degraded milk-derived basic protein fraction
  • the solution was stirred using a TK-homomixer (“MARK II 160” manufactured by PRIMIX Corporation) at 3600 rpm for 40 minutes to obtain a degraded milk-derived basic protein fraction solution containing the degraded milk-derived basic protein fraction in an amount of 2 g/100 g.
  • MARK II 160 manufactured by PRIMIX Corporation
  • the raw materials were mixed in the ratio shown in Table 14. 1 g of the resulting mixture was formed and tableted by a conventional method to obtain a skin sensitivity improving agent of the invention.
  • the skin sensitivity improving agent contained the milk-derived basic protein fraction in an amount of 100 mg/g.
  • a skin sensitivity improving cosmetic (lotion) was prepared by mixing the raw materials in the ratio shown in Table 15.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
US13/981,698 2011-01-26 2012-01-13 Sense-improving agent Abandoned US20150064158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011014441 2011-01-26
JP2011-014441 2011-01-26
PCT/JP2012/050617 WO2012102100A1 (ja) 2011-01-26 2012-01-13 感覚改善剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/050617 A-371-Of-International WO2012102100A1 (ja) 2011-01-26 2012-01-13 感覚改善剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/850,485 Division US9884095B2 (en) 2011-01-26 2015-09-10 Milk-derived basic protein fraction as skin sensitivity improving agent

Publications (1)

Publication Number Publication Date
US20150064158A1 true US20150064158A1 (en) 2015-03-05

Family

ID=46580672

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/981,698 Abandoned US20150064158A1 (en) 2011-01-26 2012-01-13 Sense-improving agent
US14/850,485 Expired - Fee Related US9884095B2 (en) 2011-01-26 2015-09-10 Milk-derived basic protein fraction as skin sensitivity improving agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/850,485 Expired - Fee Related US9884095B2 (en) 2011-01-26 2015-09-10 Milk-derived basic protein fraction as skin sensitivity improving agent

Country Status (10)

Country Link
US (2) US20150064158A1 (ja)
EP (1) EP2668956A4 (ja)
JP (1) JP5993308B2 (ja)
KR (1) KR101748907B1 (ja)
CN (1) CN103370074B (ja)
AU (1) AU2012210013C1 (ja)
CA (1) CA2823505A1 (ja)
MY (1) MY162943A (ja)
TW (1) TWI562734B (ja)
WO (1) WO2012102100A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012319579B2 (en) * 2011-10-04 2017-08-10 Megmilk Snow Brand Co., Ltd. Sense-improving agent
US9861121B2 (en) 2013-03-28 2018-01-09 Megmilk Snow Brand Co., Ltd. Milk basic protein composition and production process therefor
US9884095B2 (en) 2011-01-26 2018-02-06 Megmilk Snow Brand Co., Ltd. Milk-derived basic protein fraction as skin sensitivity improving agent

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE901672A (fr) 1985-02-07 1985-08-07 Oleofina Sa Procede de purification de proteines du lait et de ses derives.
JPH0725800B2 (ja) 1987-04-10 1995-03-22 雪印乳業株式会社 硫酸エステル化物を用いて乳からラクトフエリンを分離、精製する方法
FR2616628B1 (fr) 1987-06-19 1989-09-29 Entremont Sa Procede pour extraire des proteines du lactoserum par adsorption et elution
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
CA2005600A1 (en) * 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor
US5756686A (en) 1988-12-20 1998-05-26 Ludwig Institute For Cancer Research Peptides derived from endothelial cell growth factor
JPH0389629A (ja) * 1989-08-31 1991-04-15 Fujitsu Ltd アナログ―デジタルコンバータ
CA2086681C (en) 1990-07-13 2004-01-06 Francis J. Ballard Growth promoting agent derived from milk
JP2947657B2 (ja) * 1991-02-27 1999-09-13 森永乳業株式会社 神経成長因子産生促進剤
CA2123685C (en) 1991-11-25 2003-10-07 Hans-Arne Hansson Medicament for promoting growth of mammalian nerve
JPH05202098A (ja) 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd 乳質原料から生理活性物質の製造法
NZ253867A (en) * 1992-06-12 1996-08-27 Cephalon Inc Treating peripheral neuropathy using igf-1 or igf-3
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
JP3112637B2 (ja) 1994-09-30 2000-11-27 雪印乳業株式会社 骨強化剤
AUPQ878600A0 (en) * 2000-07-13 2000-08-03 Gropep Pty Ltd Compositions and methods for the treatment of intact skin
US20030040475A1 (en) * 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
JP2003089629A (ja) * 2001-09-18 2003-03-28 Kakunai Juyotai Kenkyusho:Kk 新規化粧品、新規外用剤及び新規浴剤の製造方法
JP4568464B2 (ja) 2001-11-07 2010-10-27 雪印乳業株式会社 記憶障害予防治療剤
WO2004024180A1 (en) * 2002-09-16 2004-03-25 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
US20040214750A1 (en) * 2003-04-28 2004-10-28 Georgiades Izolda M. Medicaments for healing skin conditions in humans
EP1937298A4 (en) 2005-10-14 2009-11-11 Auckland Uniservices Ltd USE OF LACTOFERRIN FRAGMENTS AND HYDROLYSATES
JP2007246413A (ja) * 2006-03-14 2007-09-27 Snow Brand Milk Prod Co Ltd 乳由来塩基性タンパク質含有組成物
JP5087297B2 (ja) * 2007-03-05 2012-12-05 森永乳業株式会社 インターロイキン−11産生促進剤
AR066354A1 (es) * 2007-05-01 2009-08-12 Genzyme Corp La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica
AU2008295449A1 (en) * 2007-09-07 2009-03-12 Industrial Research Limited Agents with angiogenic and wound healing activity
ES2378213T3 (es) * 2007-11-01 2012-04-10 Megmilk Snow Brand Co., Ltd. Material de alimento para inhibir la formación de osteoclastos
MY160058A (en) 2007-11-01 2017-02-15 Megmilk Snow Brand Co Ltd Bone-reinforcing food material
NZ589308A (en) * 2008-05-14 2012-11-30 Agriculture Victoria Serv Pty Use of angiogenin or angiogenin agonists for treating diseases and disorders
JP5955499B2 (ja) 2010-09-30 2016-07-20 雪印メグミルク株式会社 皮膚コラーゲン産生促進剤
JP2012077018A (ja) 2010-09-30 2012-04-19 Snow Brand Milk Products Co Ltd 皮膚コラーゲン産生促進剤
CA2823505A1 (en) 2011-01-26 2012-08-02 Megmilk Snow Brand Co., Ltd. Agent for improving peripheral sensitivity of skin
JP2013079216A (ja) * 2011-10-04 2013-05-02 Snow Brand Milk Products Co Ltd 感覚改善剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Elagamy et al. Int. Dairy J, 1996, 6:129-145. *
Fee et al. Separation and Purification Technology, 2006, 48:143-149. *
Shin et al. "Identification of lactoperoxidase in mature human milk", J. Nutr.Biochem., 2000, 11:94-102. *
Tomita et al. "Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin", J Dairy Sci., 1991, 74:4137-4142. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884095B2 (en) 2011-01-26 2018-02-06 Megmilk Snow Brand Co., Ltd. Milk-derived basic protein fraction as skin sensitivity improving agent
AU2012319579B2 (en) * 2011-10-04 2017-08-10 Megmilk Snow Brand Co., Ltd. Sense-improving agent
US9861121B2 (en) 2013-03-28 2018-01-09 Megmilk Snow Brand Co., Ltd. Milk basic protein composition and production process therefor

Also Published As

Publication number Publication date
EP2668956A1 (en) 2013-12-04
EP2668956A4 (en) 2015-11-11
AU2012210013C1 (en) 2017-06-01
KR101748907B1 (ko) 2017-06-19
JPWO2012102100A1 (ja) 2014-06-30
US9884095B2 (en) 2018-02-06
JP5993308B2 (ja) 2016-09-14
CA2823505A1 (en) 2012-08-02
AU2012210013B2 (en) 2017-02-23
TWI562734B (en) 2016-12-21
WO2012102100A1 (ja) 2012-08-02
CN103370074A (zh) 2013-10-23
CN103370074B (zh) 2015-09-02
TW201244644A (en) 2012-11-16
NZ613689A (en) 2015-09-25
US20150374797A1 (en) 2015-12-31
MY162943A (en) 2017-07-31
KR20140041427A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
EP0704218B1 (en) Bone reinforcing agent and foods and drinks product containing the same
US20110124606A1 (en) Sense-improving agent
JP3018313B2 (ja) 骨形成促進及び骨吸収防止剤
US9884095B2 (en) Milk-derived basic protein fraction as skin sensitivity improving agent
CA2349980C (en) Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof
ES2378213T3 (es) Material de alimento para inhibir la formación de osteoclastos
US20100209412A1 (en) Osteogenesis promoter
PT2208735E (pt) Matéria alimentar para promover a diferenciação de osteoblasto e inibir a diferenciação de osteoclasto
US10016481B2 (en) Sensation-improving agent
EP1602284A1 (en) Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof
JP5311804B2 (ja) 感覚改善剤
NZ613689B2 (en) Agent for improving deteriorated peripheral sensation due to aging and/or disease
EP3037100A1 (en) Muscle-atrophy-preventing agent
NZ623006B2 (en) Sensation-improving agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEGMILK SNOW BRAND CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KATOH, KEN;UEDA, NORIKO;UENO, HIROSHI;AND OTHERS;SIGNING DATES FROM 20130816 TO 20131018;REEL/FRAME:031778/0187

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION